Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors

References

• Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012; 379(9830):1984-96; PMID:22510398; http://dx.doi.org/10.1016/S0140-6736(11)61346-9
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5):459-66; PMID:19269895; http://dx.doi.org/10.1016/S1470-2045(09)70025-7
   PubMed Web of Science ®Google Scholar
• Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo. Clin. Proc. 2007; 82(10):1271-86; PMID:17908533; http://dx.doi.org/10.4065/82.10.1271
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444(7120):756-60; PMID:17051156; http://dx.doi.org/10.1038/nature05236
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821-8; PMID:14522905
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432(7015):396-401; PMID:15549107; http://dx.doi.org/10.1038/nature03128
   PubMed Web of Science ®Google Scholar
• Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23(58):9392-9400; PMID:15558011; http://dx.doi.org/10.1038/sj.onc.1208311
   PubMed Web of Science ®Google Scholar
• Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for 18 patients with glioblastoma. Clin. Dev. Immunol. 2010; vol. 2010, Article ID 689171, 18 pages; PMID:20953324; http://dx.doi.org/10.1155/2010/689171
   Google Scholar
• Chow KH, Gottschalk S. Cellular immunotherapy for high-grade glioma. Immunotherapy 2011; 3(3):423-34; PMID:21395383; http://dx.doi.org/10.2217/imt.10.110
   PubMed Web of Science ®Google Scholar
• Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012; 135(Pt 4):1042-54; PMID:22418738; http://dx.doi.org/10.1093/brain/aws042
   PubMed Web of Science ®Google Scholar
• Gerber DE, Laterra J. Emerging monoclonal antibody therapies for malignant gliomas. Expert Opin. Investig. Drugs. 2007; 16(4):477-94; PMID:17371196; http://dx.doi.org/10.1517/13543784.16.4.477
   PubMed Web of Science ®Google Scholar
• Chung DS, Shin HJ, Hong YK. A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J. Immunol. Res. 2014; 2014:326545; PMID:25009822; http://dx.doi.org/10.1155/2014/326545
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Rabbitts TH. A nomenclature to fit the organization of the human T-cell receptor gamma and delta genes. Res. Immunol. 1990; 141(7):615-8; PMID:2151348; http://dx.doi.org/10.1016/0923-2494(90)90068-A
   PubMedGoogle Scholar
• Silva-Santos B, Serre K, Norell H. gammadelta T cells in cancer. Nat. Rev. Immunol. 2015; 15(11):683-91; PMID:26449179; http://dx.doi.org/10.1038/nri3904
   PubMed Web of Science ®Google Scholar
• Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 2006; 18(5):539-46; PMID:16870417; http://dx.doi.org/10.1016/j.coi.2006.07.002
   PubMed Web of Science ®Google Scholar
• Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, Feng YH, Chang YC, Lee KD, Ou-Yang F et al. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. In vivo 2014; 28(5):1001-4; PMID:25189922
   PubMed Web of Science ®Google Scholar
• Fournie JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G. What lessons can be learned from gammadelta T cell-based cancer immunotherapy trials? Cell. Mol. Immunol. 2013; 10(1):35-41; PMID:23241899; http://dx.doi.org/10.1038/cmi.2012.39
   PubMed Web of Science ®Google Scholar
• Santolaria T, Robard M, Leger A, Catros V, Bonneville M, Scotet E. Repeated systemic administrations of both aminobisphosphonates and human Vgamma9Vdelta2 T cells efficiently control tumor development in vivo. J. Immunol. 2013; 191(4):1993-2000; PMID:23836057; http://dx.doi.org/10.4049/jimmunol.1300255
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Nakamura M, Park YS, Motoyama Y, Hironaka Y, Nishimura F, Nakagawa I, Yamada S, Matsuda R, Tamura K et al. Cytotoxic human peripheral blood-derived gammadeltaT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma. J. Neurooncol. 2014; 116(1):31-9; PMID:24062140
   PubMed Web of Science ®Google Scholar
• Cimini E, Piacentini P, Sacchi A, Gioia C, Leone S, Lauro GM, Martini F, Agrati C. Zoledronic acid enhances Vdelta2 T-lymphocyte antitumor response to human glioma cell lines. Int. J. Immunopathol. Pharmacol. 2011; 24(1):139-48; PMID:21496396
   PubMed Web of Science ®Google Scholar
• Das AV, James J, Zhao X, Rahnenfuhrer J, Ahmad I. Identification of c-Kit receptor as a regulator of adult neural stem cells in the mammalian eye: interactions with Notch signaling. Dev. Biol. 2004; 273(1):87-105; PMID:15302600; http://dx.doi.org/10.1016/j.ydbio.2004.05.023
   PubMed Web of Science ®Google Scholar
• Donnou S, Fisson S, Mahe D, Montoni A, Couez D. Identification of new CNS-resident macrophage subpopulation molecular markers for the discrimination with murine systemic macrophages. J. Neuroimmunol. 2005; 169(1-2):39-49; PMID:16169092; http://dx.doi.org/10.1016/j.jneuroim.2005.07.016
   PubMed Web of Science ®Google Scholar
• Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, Li J, Kuball J, Adams EJ, Netzer S et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset. Blood 2012; 120(11):2269-79; PMID:22767497; http://dx.doi.org/10.1182/blood-2012-05-430470
   PubMed Web of Science ®Google Scholar
• Brocard E, Oizel K, Lalier L, Pecqueur C, Paris F, Vallette FM, Oliver L. Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. Oncotarget 2015; 6(9):6840-9; PMID:25749386; http://dx.doi.org/10.18632/oncotarget.3160
   PubMed Web of Science ®Google Scholar
• Cho DY, Lin SZ, Yang WK, Lee HC, Hsu DM, Lin HL, Chen CC, Liu CL, Lee WY, Ho LH. Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant. 2013; 22(4):731-9; PMID:23594862; http://dx.doi.org/10.3727/096368912X655136
   PubMed Web of Science ®Google Scholar
• Thon N, Damianoff K, Hegermann J, Grau S, Krebs B, Schnell O, Tonn JC, Goldbrunner R. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol. Cell. Neurosci. 2010; 43(1):51-9; PMID:18761091; http://dx.doi.org/10.1016/j.mcn.2008.07.022
   PubMed Web of Science ®Google Scholar
• Silver DJ, Siebzehnrubl FA, Schildts MJ, Yachnis AT, Smith GM, Smith AA, Scheffler B, Reynolds BA, Silver J, Steindler DA. Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci 2013; 33(39):15603-17; PMID:24068827; http://dx.doi.org/10.1523/JNEUROSCI.3004-12.2013
   PubMed Web of Science ®Google Scholar
• Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Reviews 2007; 215:59-76; PMID:17291279; http://dx.doi.org/10.1111/j.1600-065X.2006.00479.x
   PubMed Web of Science ®Google Scholar
• Sandstrom A, Peigne CM, Leger A, Crooks JE, Konczak F, Gesnel MC, Breathnach R, Bonneville M, Scotet E, Adams EJ. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T cells. Immunity 2014; 40(4):490-500; PMID:24703779; http://dx.doi.org/10.1016/j.immuni.2014.03.003
   PubMed Web of Science ®Google Scholar
• Pereboeva L, Harkins L, Wong S, Lamb LS. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation. Cancer Immunol. Immunother 2015; 64(5):551-62; PMID:25676710; http://dx.doi.org/10.1007/s00262-015-1662-z
   PubMed Web of Science ®Google Scholar
• Lamb LS, Jr., Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ, King KM, Henslee-Downey PJ. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 2001; 27(6):601-6; PMID:11319589; http://dx.doi.org/10.1038/sj.bmt.1702830
   PubMed Web of Science ®Google Scholar
• Bailey SL, Carpentier PA, McMahon EJ, Begolka WS, Miller SD. Innate and adaptive immune responses of the central nervous system. Critical Rev. Immunol. 2006; 26(2):149-88; PMID:16700651; http://dx.doi.org/10.1615/CritRevImmunol.v26.i2.40
   PubMed Web of Science ®Google Scholar
• Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523(7560):337-41; PMID:26030524; http://dx.doi.org/10.1038/nature14432
   PubMed Web of Science ®Google Scholar
• Jung G, Brandl M, Eisner W, Fraunberger P, Reifenberger G, Schlegel U, Wiestler OD, Reulen HJ, Wilmanns W. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int. J. Cancer 2001; 91(2):225-30; PMID:11146449; http://dx.doi.org/10.1002/1097-0215(200002)9999:9999%3c::AID-IJC1038%3e3.3.CO;2-7
   PubMed Web of Science ®Google Scholar
• Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, Gudeman S, Varia MA. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. . Neuro-oncol. 1999; 45(2):141-57; PMID:10778730
   PubMed Web of Science ®Google Scholar
• Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg. Focus. 2000; 9(6):e9; PMID:16817692; http://dx.doi.org/10.3171/foc.2000.9.6.10
   PubMedGoogle Scholar
• Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z; ASPECT Study Group. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(9):823-33; PMID:23850491; http://dx.doi.org/10.1016/S1470-2045(13)70274-2
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011; 49(1):34-41; PMID:21111853; http://dx.doi.org/10.1016/j.bone.2010.11.008
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase I/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol. Immunother. 2011; 60(8):1075-84; PMID:21519826; http://dx.doi.org/10.1007/s00262-011-1021-7
   PubMed Web of Science ®Google Scholar
• Coleman RE. Risks and benefits of bisphosphonates. Br. J. Cancer 2008; 98(11):1736-40; PMID:18506174; http://dx.doi.org/10.1038/sj.bjc.6604382
   PubMed Web of Science ®Google Scholar
• Weiss HM, Pfaar U, Schweitzer A, Wiegand H, Skerjanec A, Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab. Dispos. 2008; 36(10):2043-9; PMID:18625688
   PubMed Web of Science ®Google Scholar
• Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N. Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate. J. Immunol. 2003; 170(7):3608-13; PMID:12646624; http://dx.doi.org/10.4049/jimmunol.170.7.3608
   PubMed Web of Science ®Google Scholar
• Sabatino R, Antonelli A, Battistelli S, Schwendener R, Magnani M, Rossi L. Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. PloS One 2014; 9(6):e101260; PMID:24968029; http://dx.doi.org/10.1371/journal.pone.0101260
   PubMedGoogle Scholar
• Rietkotter E, Menck K, Bleckmann A, Farhat K, Schaffrinski M, Schulz M, Hanisch UK, Binder C, Pukrop T. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion. Oncotarget 2013; 4(9):1449-60; PMID:24036536; http://dx.doi.org/10.18632/oncotarget.1201
   PubMed Web of Science ®Google Scholar